Last updated: March 27, 2025
Sponsor: Edwards Lifesciences
Overall Status: Active - Recruiting
Phase
N/A
Condition
Congestive Heart Failure
Treatment
EVOQUE
Clinical Study ID
NCT06833476
EVOQUE CED
Ages > 65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Medicare eligible patients who have received an EVOQUE device or are EVOQUE eligible and have at least severe Tricuspid Regurgitation
Exclusion
Exclusion Criteria:
Commercially insured patients who have received an EVOQUE device or are EVOQUE eligible or Medicare eligible patients with less than severe Tricuspid Regurgitation
Study Design
Total Participants: 2044
Treatment Group(s): 1
Primary Treatment: EVOQUE
Phase:
Study Start date:
March 19, 2025
Estimated Completion Date:
December 31, 2032
Study Description
Connect with a study center
Edwards Lifesciences
Irvine, California 92614
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.